The crux of systemic treatment of patients with ER+ BC relies on drugs that either prevent the synthesis of the estrogen ligand by inhibiting the aromatase enzyme, competitively inhibiting ligand binding, or degrading the cellular receptor for the ligand5. This evidence concerns the gene ESR1 and breast cancer.